Enriched CD44+/CD24- population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 153-159

  Ma, Fei ^a   Li, Huihui ^b   Wang, Haijuan ^a   Shi, Xiuqing ^a   Fan, Ying ^a   Ding, Xiaoyan ^a   Lin, Chen ^a   Zhan, Qimin ^a   Qian, Haili ^a   Xu, Binghe ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cancer stem cells; CD44+ CD24 ; Triple negative breast cancer

Indexed keywords

CD24 ANTIGEN; HERMES ANTIGEN; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; CANCER STEM CELL; CARCINOGENICITY; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CANCER TRANSPLANTATION; CD44(+)/CD24(-).; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; NONOBESE DIABETIC MOUSE; PAGET NIPPLE DISEASE; PATHOLOGY; PHENOTYPE; SCID MOUSE; TUMOR CELL LINE;

CANCER STEM CELLS; CD44(+)/CD24(-).; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; CARCINOMA, DUCTAL, BREAST; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PHENOTYPE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84908703665     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.06.022     Document Type: Article

References (39)

1. Fornier M., Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J. 2012, 18:41-51.
2. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8418-8423.
3. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience. Nat. Rev. Clin. Oncol 2010, 7:683-692.
4. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res 2004, 10:5367-5374.
5. Ichim C.V., Wells R.A. First among equals: the cancer cell hierarchy. Leuk. Lymphoma 2006, 47:2017-2027.
6. Campbell L.L., Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution. Cell Cycle 2007, 6:2332-2338.
7. Song L.L., Miele L. Cancer stem cells - an old idea that's new again: implications for the diagnosis and treatment of breast cancer. Expert Opin. Biol. Ther 2007, 7:431-438.
8. Lu X., Xu K., Lu H., Yin Y., Ma C., Liu Y., et al. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct. Pathol 2011, 35:72-78.
9. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
10. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
11. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124.
12. Reuben J.M., Lee B.N., Gao H., Cohen E.N., Mego M., Giordano A., et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24lo cancer stem cell phenotype. Eur. J. Cancer 2011, 47:1527-1536.
13. Giatromanolaki A., Sivridis E., Fiska A., Koukourakis M.I. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med. Oncol 2011, 28:745-752.
14. Idowu M.O., Kmieciak M., Dumur C., Burton R.S., Grimes M.M., Powers C.N., et al. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol 2012, 43:364-373.
15. Mylona E., Giannopoulou I., Fasomytakis E., Nomikos A., Magkou C., Bakarakos P., et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum. Pathol 2008, 39:1096-1102.
16. Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res 2005, 11:1154-1159.
17. Hammond M.E., Hayes D.F., Wolff A.C., Mangu P.B., Temin S. American society of clinical oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract 2010, 6:195-197.
18. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol 2007, 25:118-145.
19. Miyoshi Y., Kurosumi M., Kurebayashi J., Matsuura N., Takahashi M., Tokunaga E., et al. Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers. Cancer Lett 2008, 264:44-53.
20. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
21. Subik K., Lee J.F., Baxter L., Strzepek T., Costello D., Crowley P., et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl.) 2010, 4:35-41.
22. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
23. Smorodchenko A., Rupprecht A., Sarilova I., Ninnemann O., Brauer A.U., Franke K., et al. Comparative analysis of uncoupling protein 4 distribution in various tissues under physiological conditions and during development. Biochim. Biophys. Acta 2009, 1788:2309-2319.
24. Rakha E.A., El-Sayed M.E., Reis-Filho J.S., Ellis I.O. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 2008, 52:67-81.
25. Stingl J., Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 2007, 7:791-799.
26. Payne S.J., Bowen R.L., Jones J.L., Wells C.A. Predictive markers in breast cancer - the present. Histopathology 2008, 52:82-90.
27. Azzam D.J., Zhao D., Sun J., Minn A.J., Ranganathan P., Drews-Elger K., et al. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in gamma-secretase inhibitor drug responses. EMBO Mol. Med 2013, 5:1502-1522.
28. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
29. Ricardo S., Vieira A.F., Gerhard R., Leitao D., Pinto R., Cameselle-Teijeiro J.F., et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol 2011, 64:937-946.
30. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest 2009, 119:1420-1428.
31. Wu Y., Zhou B.P. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40:643-650.
32. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
33. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
34. Peach R.J., Hollenbaugh D., Stamenkovic I., Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J. Cell Biol 1993, 122:257-264.
35. Bourguignon L.Y., Zhu H., Shao L., Chen Y.W. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J. Biol. Chem 2000, 275:1829-1838.
36. Liekens S., Schols D., Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr. Pharm. Des 2010, 16:3903-3920.
37. Chu Q.D., Holm N.T., Madumere P., Johnson L.W., Abreo F., Li B.D. Chemokine receptor CXCR4 overexpression predicts recurrence for hormone receptor-positive, node-negative breast cancer patients. Surgery 2011, 149:193-199.
38. Liu D., Guo H., Li Y., Xu X., Yang K., Bai Y. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS ONE 2012, 7:e31251.
39. Mendes O., Kim H.T., Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin. Exp. Metastasis 2005, 22:237-246.